Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy

• Published in: BMC urology 2022-07, Vol.22 (1), p.1-96, Article 96
• Main Authors: Wrenger, Robin, Jüptner, Michael, Marx, Marlies, Zhao, Yi, Zuhayra, Maaz, Caliebe, Amke, Osmonov, Daniar, Lützen, Ulf
• Format: Article
• Language: English
• Subjects: Alkaline phosphatase; Antigens; C-reactive protein; Cancer therapies; Care and treatment; Castration; Chemotherapy; Comparative analysis; Hemoglobin; L-Lactate dehydrogenase; Laboratories; Lactic acid; Liver; Lu-177-PSMA-617; Medical prognosis; Medical research; Medicine, Experimental; Metastases; Metastasis; Patient outcomes; Patients; Phosphatases; Prostate cancer; Prostate-specific antigen; Radioligand therapy, castration-resistant prostate cancer; Statistical analysis; Survival; Survival analysis; Urology; γ-Glutamyltransferase
• ISSN: 1471-2490; 1471-2490
• DOI: 10.1186/s12894-022-01050-3

Background Systemic Lutetium-177 prostate-specific membrane antigen-617 radioligand therapy (Lu-177-PSMA-617-RLT) is a novel treatment approach in patients suffering from metastasized castration-resistant prostate cancer. Nonetheless, a therapeutic response may fail to appear in a proportion of patients. This study aims to identify routinely obtainable pre- and intratherapeutic parameters to allow a prediction of overall survival in patients receiving Lu-177-PSMA-617 radioligand therapy. Methods Between January 2015 and December 2020 52 patients treated with a total of 146 cycles Lu-177-PSMA-617-RLT were retrospectively analysed in a single-center trial. The median overall survival time (OS) was compared to pre-therapeutic serological parameters, the extend of metastatic spread and previously performed therapies using Kaplan-Meier estimators and multivariate Cox-regression. Bonferroni-Holm correction was performed on all statistical tests. Results The median OS of all patients was 55.6 weeks. Multivariate Cox-regression revealed significant lower survival for decreased pretherapeutic hemoglobin levels (HR 0.698 per g/dl; 95%-CI 0.560-0.872; p = 0.001), increased lactate dehydrogenase (LDH) levels (HR 1.073 per 25 U/l; 95%-CI 1.024-1.125; p = 0.003) and the presence of hepatic metastasis (HR 6.981; 95%-CI 2.583-18.863; p < 0.001). Increased pretherapeutic c-reactive protein (CRP), alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) levels were also associated with a shorter survival. A prostate-specific antigen decline after one therapy cycle did not significantly correlate with an increased survival. No significant relations were observed between overall survival time and other serological parameters or previously performed therapies. Conclusion Pre-therapeutic hemoglobin and LDH levels, as well as the presence of hepatic metastasis are independent predictors of overall survival in patients receiving Lu-177-PSMA-617-RLT. CRP, ALP and GGT levels cloud be utilized as additional decision aids when a Lu-177-PSMA-617-RLT is intended. Trial Registration Not applicable (retrospective observational study). Keywords: Lu-177-PSMA-617, Radioligand therapy, castration-resistant prostate cancer, Survival analysis